New drugs to treat triple negative breast cancer using proteasome inhibitors
Novel proteasome inhibitors targeting both beta5 and beta2 subunits for treatment of triple negative breast cancer
This study is looking at new treatments for triple negative breast cancer by creating special drugs that can better fight the cancer cells, especially for patients who haven't had success with current options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11042265 on NIH RePORTER |
What this research studies
This research focuses on developing novel proteasome inhibitors that target specific subunits to improve treatment outcomes for patients with triple negative breast cancer. The approach aims to overcome resistance to existing proteasome inhibitors by simultaneously inhibiting two key components of the proteasome, which may enhance the effectiveness of the treatment. By understanding how these inhibitors affect tumor cells, the research seeks to provide a more effective therapy for patients who currently have limited options. The study will involve laboratory experiments and potentially clinical trials to evaluate the safety and efficacy of these new drugs.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who have not responded well to existing treatments.
Not a fit: Patients with other types of breast cancer or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with triple negative breast cancer, improving survival rates and quality of life.
How similar studies have performed: While proteasome inhibitors have been used successfully in treating multiple myeloma, this specific approach targeting triple negative breast cancer is novel and has not been extensively tested.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Lin, Gang — Weill Medical Coll of Cornell Univ
- Study coordinator: Lin, Gang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.